These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36946392)

  • 1. [Cerebrolysin in the treatment of cognitive impairment].
    Bogolepova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):20-25. PubMed ID: 36946392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MG; Tabet N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrolysin for vascular dementia.
    Cui S; Chen N; Yang M; Guo J; Zhou M; Zhu C; He L
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31710397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
    Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on cerebrolysin in dementia.
    Plosker GL; Gauthier S
    CNS Drugs; 2010 Mar; 24(3):263-6. PubMed ID: 20155999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
    Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
    Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Isaac MG; Clark AR; Rusted J; Tabet N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002854. PubMed ID: 23152215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué I Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010783. PubMed ID: 25740785
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.